Nilsson, Boel
Bylund, Johan
Halldin, Magnus M.
Rother, Matthias
Rein-Hedin, Erik
Önnestam, Kristin
Segerdahl, Märta
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 23 October 2023
Accepted: 2 February 2024
First Online: 14 February 2024
Declarations
:
: The current clinical studies were conducted in compliance with the study protocol, the International Council for Harmonization Guideline for Good Clinical Practice, all applicable regulatory requirements, and in accordance with the latest revision of the Ethical Principles for Medical Research Involving Human Subjects (the Declaration of Helsinki). The study protocol and all applicable study-related documentation were approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. Signed informed consent was obtained from the study participants prior to any study-related activities. Both studies were conducted at the First in Human unit of CTC Clinical Trial Consultants AB, Uppsala, Sweden.
: BN, KÖ, and MS are employees of AlzeCure Pharma AB. MR and MMH are paid consultants of AlzeCure Pharma AB. MR represents AlzeCure Pharma AB as a medical expert on multiple safety review committees. ER-H and JB are employees of CTC Clinical Trial Consultants AB, a contract service provider for AlzeCure Pharma AB.